Agilent Technologies Inc (NYSE:A) has earned an average rating of “Buy” from the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $86.91.
Several equities research analysts have weighed in on the company. Deutsche Bank restated a “buy” rating and set a $90.00 target price on shares of Agilent Technologies in a research note on Thursday, February 21st. Robert W. Baird reiterated a “buy” rating and issued a $82.00 price target (up from $77.00) on shares of Agilent Technologies in a research note on Wednesday, February 20th. Needham & Company LLC reiterated a “buy” rating and issued a $88.00 price target (up from $77.00) on shares of Agilent Technologies in a research note on Monday, February 25th. Zacks Investment Research cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. Finally, Barclays increased their price target on Agilent Technologies from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Thursday, February 21st.
Shares of Agilent Technologies stock traded up $0.41 on Friday, hitting $81.02. The stock had a trading volume of 9,095 shares, compared to its average volume of 1,939,267. Agilent Technologies has a twelve month low of $60.42 and a twelve month high of $81.76. The company has a current ratio of 3.39, a quick ratio of 2.79 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $25.38 billion, a price-to-earnings ratio of 29.05, a PEG ratio of 2.22 and a beta of 1.38.
Agilent Technologies announced that its board has authorized a share buyback plan on Monday, November 19th that authorizes the company to repurchase $1.75 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 8.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.
In related news, VP Mark Doak sold 16,421 shares of the stock in a transaction on Friday, February 22nd. The stock was sold at an average price of $77.95, for a total value of $1,280,016.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael R. Mcmullen sold 17,491 shares of the stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $75.00, for a total value of $1,311,825.00. Following the completion of the sale, the chief executive officer now owns 456,430 shares of the company’s stock, valued at $34,232,250. The disclosure for this sale can be found here. Insiders sold 74,171 shares of company stock valued at $5,764,185 over the last 90 days.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Parallel Advisors LLC grew its stake in shares of Agilent Technologies by 3.9% in the 4th quarter. Parallel Advisors LLC now owns 4,002 shares of the medical research company’s stock valued at $269,000 after buying an additional 149 shares during the period. Fruth Investment Management grew its stake in shares of Agilent Technologies by 0.3% in the 4th quarter. Fruth Investment Management now owns 45,351 shares of the medical research company’s stock valued at $3,059,000 after buying an additional 150 shares during the period. BOKF NA grew its stake in shares of Agilent Technologies by 1.4% in the 4th quarter. BOKF NA now owns 11,229 shares of the medical research company’s stock valued at $757,000 after buying an additional 158 shares during the period. Sumitomo Life Insurance Co. grew its stake in shares of Agilent Technologies by 1.3% in the 4th quarter. Sumitomo Life Insurance Co. now owns 13,394 shares of the medical research company’s stock valued at $904,000 after buying an additional 178 shares during the period. Finally, Mission Wealth Management LP grew its stake in shares of Agilent Technologies by 2.1% in the 4th quarter. Mission Wealth Management LP now owns 8,629 shares of the medical research company’s stock valued at $582,000 after buying an additional 179 shares during the period.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Article: Understanding Average Daily Trade Volume
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.